摘要
目的比较长春瑞滨和顺铂（NP）方案联合西乐葆与NP方案治疗晚期非小细胞肺癌（non-small-cell lungcancer，NSCLC）的疗效和安全性。方法65例ⅢB/IV期NSCLC患者随机分为A组和B组。A组32例，化疗方案NP方案联合西乐葆，长春瑞滨25 mg/m^2第1、8天静脉注射，顺铂75 mg/m^2第1、2天静脉滴注，西乐葆400 mg2次/日，第1-12天口服，21 d为一个周期；B组33例，化疗方案为NP方案，用法同A组。结果A组与B组有效率分别为35.5%和26.7%（P=0.457），临床受益率分别为87.1%和66.7%（P=0.058），1年生存率分别为58.1%和36.7%（P=0.094），中位生存期分别为12个月和9.2个月（P=0.062）。而36例肺腺癌中，A组1年生存率为64.7%，显著高于B组的26.3%（P=0.021）；且A组中位生存期为12.5个月，明显高于B组的8.7个月（P=0.033）。A组恶心/呕吐的发生率为67.7%，明显高于B组的40.0%（P=0.03），而白细胞下降、恶心呕吐、脱发、静脉炎、神经毒性和血小板减少等副作用之间差异无统计学意义。结论NP方案联合西乐葆治疗晚期NSCLC有效，安全性好。肺腺癌的1年生存率及中位生存期均显著高于NP方案组。
Objective To investigate efficacy and safety of first-line regime of Vinorelbine and Cisplatin （NP） combined with cyclooxygenase-2 inhibitor celecoxib in treating advanced non-small-cell lung cancer （NSCLC） patientsMethods Sixty five NSCLC patients were randomly assigned to group A and group B. In the group A, 32 patients were treated with Vinorelbine 25 mg/m^2 iv on days 1 and 8, Cisplatin 75 mg/m^2 iv on day 1 and Celecoxib 400 nag bid orally on days 1 to 12, repeated every 21 days. In group B, 33 cases were treated with NP regimen only. Results Compared with group B, the response rate in group A was 35 . 5 % vs 26.7%（P= 0.457）, clinical benifit rate was 87.1% vs 66.7% （P = 0. 058）, one-year survival rate was 58.1% vs 36.7 % （P = 0. 094） and median survival time was 12 months vs 9.2 months （ P = 0. 062） respectively. In 36 cases of lung adenocarcinoma, one-year survival rate and median survival time were significantly higher in group A than in group B （64.7 % vs. 26.3 %, P = 0. 021 ）and（12.5 months vs 8.7 months, P = 0. 033） respectively. Nausea/vomiting occurred significantly more frequently in gruop A than in gruop B （67.74 % vs 40.0 %, P = 0. 030）. Other side-effects had no statistical difference between two groups. Conclusion The regimen of NP combined with COX-2 inhibitor Celecoxib is effective and tolerable as the first-line treatment in advanced NSCLC. The one-year survival rate and median survival time were significantly higher in those treated with NP plus Celecoxib.
出处
《同济大学学报（医学版）》
CAS
2007年第5期87-90,94,共5页
Journal of Tongji University(Medical Science)
关键词
环氧化酶2抑制剂
长春瑞滨
顺铂
化疗
非小细胞肺肿瘤
cyclooxygenase-2 inhibitor
vinorelbine
cisplatin
chemotherapy
non-small cell lung cancer
